Shareholder Communications

For shareholder queries, please email  You will receive an acknowledgement of your question, and a commitment to address your question in the periodic answers sessions.  Valirx commits to answering questions in a clear, concise and factual manner.  Where a question cannot be answered due to regulatory or commercial sensitivity reasons, the question will still be reported, with the reason for no answer being provided.

Answers Sessions:June-2020-Answers.pdf